The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Validation, 2011Lamp-2a as a Therapeutic Target in Parkinson's Disease
Objective/Rationale:
Multiple pieces of evidence converge on the notion that accumulation of the protein alpha-synuclein is important for Parkinson’s disease (PD) pathogenesis. One of the ways through... -
LRRK2, 2010The Trondheim LRRK2 Cohort Program
Objective/Rationale:
We are examining a Symptoms & Side Effects family members of LRRK2-PD patients looking for clinical features indicating differences between mutation carriers and non-carriers... -
LRRK2, 2010Genetic and Environmental Modifiers for LRRK2-Associated PD
Objective/Rationale:
In the last decades, mutations of several genes have been found to cause familial Parkinson’s disease (PD) and variants of these genes can also increase the risk for developing... -
MJFF Research Grant, 2010PROGENI Family Study
Objective/Rationale:
The LRRK2 Consortium is designing studies to allow researchers to identify the key genetic, biological and clinical features of LRRK2 associated PD that could lead to improved... -
Alpha-Synuclein Therapeutics, 2010Anti-amyloid Oligomer Monoclonal Antibodies for Treatment of Parkinson's Disease
Objective/Rationale:
The goal of this project is to evaluate the interaction of a panel of conformation dependent, aggregation specific anti-amyloid monoclonal antibodies with alpha-synuclein... -
Pharmacodynamic Biomarkers of LRRK2 Activity, 2010LRRK2 Dimerization as Pharmacodynamic Biomarkers of Activity
Objective/Rationale:
A promising target for neuroprotective therapies in Parkinson’s disease has emerged in the LRRK2 protein kinase. Proteins with similarities to LRRK2 have been successfully...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.